<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="case-report"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Cureus</journal-id><journal-id journal-id-type="iso-abbrev">Cureus</journal-id><journal-id journal-id-type="issn">2168-8184</journal-id><journal-title-group><journal-title>Cureus</journal-title></journal-title-group><issn pub-type="epub">2168-8184</issn><publisher><publisher-name>Cureus</publisher-name><publisher-loc>Palo Alto (CA)</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40190901</article-id><article-id pub-id-type="pmc">PMC11972658</article-id><article-id pub-id-type="doi">10.7759/cureus.80226</article-id><article-categories><subj-group subj-group-type="heading"><subject>Gastroenterology</subject></subj-group><subj-group><subject>Internal Medicine</subject></subj-group></article-categories><title-group><article-title>Unexplained Gastric Ulcer: Role of Cinacalcet</article-title></title-group><contrib-group><contrib contrib-type="editor"><name><surname>Muacevic</surname><given-names>Alexander</given-names></name></contrib><contrib contrib-type="editor"><name><surname>Adler</surname><given-names>John R</given-names></name></contrib></contrib-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Son</surname><given-names>Christine</given-names></name><xref rid="aff-1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Kalapala</surname><given-names>Joshua</given-names></name><xref rid="aff-2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Leya</surname><given-names>Jeff</given-names></name><xref rid="aff-1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Desai</surname><given-names>Nirmal</given-names></name><xref rid="aff-3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name><surname>Banerjee</surname><given-names>Promila</given-names></name><xref rid="aff-4" ref-type="aff">4</xref></contrib></contrib-group><aff id="aff-1">
<label>1</label>
Internal Medicine, Loyola University Medical Center, Maywood, USA </aff><aff id="aff-2">
<label>2</label>
Gastroenterology, Loyola University Chicago Stritch School of Medicine, Maywood, USA </aff><aff id="aff-3">
<label>3</label>
Gastroenterology, Loyola University Medical Center, Maywood, USA </aff><aff id="aff-4">
<label>4</label>
Gastroenterology and Hepatology, Loyola University Edward Hines Veterans Affairs (VA) Hospital, Hines, USA </aff><author-notes><corresp id="cor1">
Christine Son <email>sonc9421@gmail.com</email>
</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>7</day><month>3</month><year>2025</year></pub-date><pub-date date-type="collection" publication-format="electronic"><month>3</month><year>2025</year></pub-date><volume>17</volume><issue>3</issue><elocation-id>e80226</elocation-id><history><date date-type="accepted"><day>6</day><month>3</month><year>2025</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2025, Son et al.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Son et al.</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><self-uri xlink:href="https://www.cureus.com/articles/326122-unexplained-gastric-ulcer-role-of-cinacalcet">This article is available from https://www.cureus.com/articles/326122-unexplained-gastric-ulcer-role-of-cinacalcet</self-uri><abstract><p>Peptic ulcer disease (PUD) most commonly arises as a complication of <italic>Helicobacter pylori</italic> (<italic>H. pylori) </italic>or impaired mucosal defense mechanisms against acid exposure by medications such as non-steroidal anti-inflammatory drugs (NSAIDs). Hypercalcemia can present with peptic ulcer-related symptoms, and cinacalcet is an effective medical treatment for primary hyperparathyroidism (PHPT) for non-surgical candidates. We present a case of a 66-year-old male patient with a history of primary hypercalcemia as a result of hyperparathyroidism, on chronic cinacalcet, who was found to have gastric ulcers on endoscopy.&#x000a0;After the reduction of the cinacalcet dose in one year, there was a complete resolution of inflammation in the gastric body.&#x000a0;</p></abstract><kwd-group kwd-group-type="author"><kwd>cinacalcet</kwd><kwd>gastric ulcer</kwd><kwd>hypercalcemia</kwd><kwd>peptic ulcer disease (pud)</kwd><kwd>primary hyperparathyroidism (phpt)</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Peptic ulcer disease (PUD) often occurs in areas exposed to acid and pepsin as a break in the mucosal lining of the stomach or proximal intestine. It most commonly occurs as a complication of <italic>Helicobacter pylori</italic> (<italic>H. pylori</italic>) infection [<xref rid="REF1" ref-type="bibr">1</xref>]. Medications are the next-most common cause of PUD, specifically nonsteroidal anti-inflammatory drug (NSAID)-associated gastropathy [<xref rid="REF2" ref-type="bibr">2</xref>]. It is thought that NSAIDs impair prostaglandin-mediated mucosal protection against acidic damage, leading to gastric ulcers [<xref rid="REF3" ref-type="bibr">3</xref>]. In disorders like Zollinger-Ellison syndrome and antral G-cell hyperfunction, gastrin stimulates gastric acid hypersecretion, leading to peptic ulcer formations. However, the significance of hormonal abnormalities in peptic ulcers with normal gastrin levels is not well understood [<xref rid="REF4" ref-type="bibr">4</xref>]. Other causes of gastric ulcers are not well defined, and idiopathic gastric ulcers are diagnosed when there is no identifiable cause and ulcers arise spontaneously.</p><p>Primary hyperparathyroidism (PHPT) leads to an elevation in parathyroid hormone (PTH) and resulting hypercalcemia. Prior studies have shown that extracellular calcium stimulates gastrin and gastric acid secretion in humans, specifically with oral calcium carbonate ingestion in duodenal ulcer patients [<xref rid="REF5" ref-type="bibr">5</xref>-<xref rid="REF9" ref-type="bibr">9</xref>]. The extracellular calcium-sensing receptor (CaSR) on the parathyroid cell surface negatively regulates the PTH secretion. Calcium-sensing receptor is expressed not only in cells secreting calcium-regulating hormones, which are parathyroid cells and thyroid C-cells, but also in cells involved in calcium transport, such as intestinal cells, osteoblasts, and cells of nephron segments [<xref rid="REF10" ref-type="bibr">10</xref>]. The CaSR expressed on the surface of G cells and parietal cells offers a potential mechanism for calcium&#x02019;s effect on gastrin and gastric acid secretion and the resulting peptic ulcer formation [<xref rid="REF11" ref-type="bibr">11</xref>].</p><p>Cinacalcet is a drug that acts as a calcimimetic by activating the allosteric site of CaSR [<xref rid="REF12" ref-type="bibr">12</xref>], thereby mobilizing intracellular calcium stores and inhibiting PTH secretion. Cinacalcet reduces both serum calcium and PTH levels in PHPT [<xref rid="REF12" ref-type="bibr">12</xref>, <xref rid="REF13" ref-type="bibr">13</xref>], serving as an effective medical treatment for non-surgical candidates [<xref rid="REF13" ref-type="bibr">13</xref>].</p><p>This article was previously presented as a meeting abstract at the 2024 American College of Gastroenterology (ACG) Annual Meeting on October 28, 2024.</p></sec><sec sec-type="cases"><title>Case presentation</title><p>A 66-year-old male patient with a history of thyroid cancer status post&#x000a0;thyroidectomy and PHPT status post parathyroidectomy, who was treated with cinacalcet for recurrent hypercalcemia, presented with a six-month history of epigastric pain and reflux symptoms. A few months after the symptom onset, he was incidentally found to have increased wall thickening and dilatation of the upper esophagus on an annual low-dose CT chest performed for pulmonary nodule surveillance. An esophagogastroduodenoscopy (EGD) on this occasion revealed mucosa consistent with Barrett&#x02019;s esophagus, a distal esophageal ulcer, and diffuse erythematous changes in the gastric mucosa.&#x000a0;A follow-up EGD was scheduled for eight weeks after treatment of the esophageal ulcer with omeprazole 40 mg twice a day (BID).</p><p>The patient initially had chronic parathyroiditis, or chronic inflammation or overactivation&#x000a0;of the right superior and inferior parathyroid glands, in 2009. He subsequently underwent removal of the right inferior parathyroid gland with right superior parathyroid autotransplantation. Post-operatively, calcium level was normal; however, PTH continued to be elevated, and hypercalcemia recurred a few months later. The patient was eventually started on cinacalcet 60 mg twice daily in April 2015 for this recurrent hypercalcemia.</p><p>On repeat EGD, the esophagitis was healed, but a new 4x3 cm patch of exudate and friable mucosa was seen within the gastric body (Figure <xref rid="FIG1" ref-type="fig">1</xref>).</p><fig position="anchor" fig-type="figure" id="FIG1"><label>Figure 1</label><caption><title>The index esophagogastroduodenoscopy (EGD) showed a 4x3 cm patch of exudate&#x000a0;and scattered erosions in the gastric body.</title></caption><graphic xlink:href="cureus-0017-00000080226-i01" position="float"/></fig><p>Given the benign-appearing ulceration (Figure <xref rid="FIG2" ref-type="fig">2</xref>), this was thought to be medication-induced and related to hypercalcemia.</p><fig position="anchor" fig-type="figure" id="FIG2"><label>Figure 2</label><caption><title>The H&#x00026;E slide of gastric mucosa (10x magnification) </title><p>Ulcerated gastric mucosa at the center with surrounding free-floating inflamed necrotic debris is noted. Gastric mucosa with normal architecture is seen at the peripheries.</p></caption><graphic xlink:href="cureus-0017-00000080226-i02" position="float"/></fig><p>Immunohistochemistry (IHC) staining for <italic>H. pylori</italic> was negative (Figure <xref rid="FIG3" ref-type="fig">3</xref>), and the patient was not on long-term NSAID use.</p><fig position="anchor" fig-type="figure" id="FIG3"><label>Figure 3</label><caption><title>Immunohistochemistry (IHC) staining for Helicobacter pylori (20x magnification) was negative.</title></caption><graphic xlink:href="cureus-0017-00000080226-i03" position="float"/></fig><p>A thorough review of the patient's medication list found cinacalcet as the possible culprit. The patient was referred for parathyroidectomy to discontinue cinacalcet completely. However, given the complexity of the procedure, surgery was deferred, and the cinacalcet dose was decreased to 30 mg from 60 mg twice daily. The omeprazole was continued, and he was started on Carafate, with plans for surveillance EGDs. Serial EGDs at six and nine months showed improvement in non-bleeding gastric ulcers and erythematous mucosa in the gastric body (Figure <xref rid="FIG4" ref-type="fig">4</xref>).</p><fig position="anchor" fig-type="figure" id="FIG4"><label>Figure 4</label><caption><title>A third esophagogastroduodenoscopy (EGD) performed nine months after the index study under regular white light (a) and flexible spectral imaging color enhancement (FICE)(b). </title><p>Overall, these demonstrated significant improvement in the area in question. Biopsy with chronic active inflammation, lymphoid aggregate, and reactive/regenerative changes; negative for <italic>Helicobacter pylori</italic>.</p></caption><graphic xlink:href="cureus-0017-00000080226-i04" position="float"/></fig><p>After one year, there was a complete resolution of inflammation in the gastric body (Figure <xref rid="FIG5" ref-type="fig">5</xref>).&#x000a0;</p><fig position="anchor" fig-type="figure" id="FIG5"><label>Figure 5</label><caption><title>Fourth esophagogastroduodenoscopy (EGD) one year after the index study under regular white light.</title><p>(a) and (b): Complete resolution of inflammation in the gastric body is noted.&#x000a0;</p></caption><graphic xlink:href="cureus-0017-00000080226-i05" position="float"/></fig></sec><sec sec-type="discussion"><title>Discussion</title><p>There have been associations between primary hypercalcemia and peptic ulcer-related symptoms, with approximately 12% of patients with PHPT presenting with epigastric pain and nausea [<xref rid="REF14" ref-type="bibr">14</xref>]. Cases of peptic ulcer perforation as the initial presentation of PHPT are extremely rare but have been reported in the literature. The current theory is that serum calcium activates gastrin cell calcium receptors, ultimately resulting in increased gastric acid production and PUD [<xref rid="REF15" ref-type="bibr">15</xref>].&#x000a0;</p><p>Our patient&#x02019;s calcium and PTH levels were normal for many years leading up to his presentation. Therefore, it is likely a significant contribution from a different culprit was present in his gastric ulcer formation. The one identifiable source for this patient was cinacalcet, which is thought to activate the same gastrin cell calcium receptors that calcium does. In theory, gastrin cell calcium receptor activation by cinacalcet can then lead to the formation of PUD, especially over many years of activation.&#x000a0;</p><p>In a small, randomized placebo-controlled study, changes in gastrin levels in the cinacalcet-treated group were significantly higher than those in the placebo group [<xref rid="REF11" ref-type="bibr">11</xref>]. The study suggested that activating CaSR in the stomach with an allosteric CaSR modulator, cinacalcet may lead to an increase in serum gastrin acid levels and basal gastric acid secretion. Interestingly, lower doses of cinacalcet of 15 to 30 mg daily for 11 days caused no GI symptoms in healthy participants. In contrast, dialysis patients with secondary hyperparathyroidism randomized to a 30 to 180 mg daily dose of cinacalcet had a 13% to 14% higher incidence of nausea and vomiting than those on placebo [<xref rid="REF16" ref-type="bibr">16</xref>]. The most commonly attributed side effects of cinacalcet are nausea, vomiting, and generalized GI discomfort [<xref rid="REF11" ref-type="bibr">11</xref>, <xref rid="REF16" ref-type="bibr">16</xref>-<xref rid="REF18" ref-type="bibr">18</xref>]. While GI pathology arising as a result of long-term cinacalcet use is not well studied, this case suggests a dose-dependent association between cinacalcet use and GI side effects.</p></sec><sec sec-type="conclusions"><title>Conclusions</title><p>This case report is one of the first to show that PUD may be induced by cinacalcet use. While no definite causation can be established, one year after the dose reduction of cinacalcet, complete resolution of gastric inflammation was seen on endoscopy. This case highlights that not only hypercalcemia from PHPT can cause PUD but also the treatment of hypercalcemia with cinacalcet. While cinacalcet is effective in treating hypercalcemia, more studies are needed to examine the effect of the long-term use of cinacalcet on the risk of gastric ulcer development.</p></sec></body><back><fn-group content-type="conflict"><title>Disclosures</title><fn fn-type="COI-statement"><p><bold>Human subjects:</bold> Consent for treatment and open access publication was obtained or waived by all participants in this study. Edwards Hines Veteran Affairs (VA) Hospital Institutional Review Board (IRB) issued approval (exempt).</p><p><bold>Conflicts of interest:</bold> In compliance with the ICMJE uniform disclosure form, all authors declare the following:</p><p><bold>Payment/services info:</bold> All authors have declared that no financial support was received from any organization for the submitted work.</p><p><bold>Financial relationships:</bold> All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work.</p><p><bold>Other relationships:</bold> All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.</p></fn></fn-group><fn-group content-type="other"><title>Author Contributions</title><fn fn-type="other"><p><bold>Concept and design:</bold>&#x000a0; Christine Son, Nirmal Desai, Promila Banerjee, Joshua Kalapala</p><p><bold>Acquisition, analysis, or interpretation of data:</bold>&#x000a0; Christine Son, Jeff Leya, Promila Banerjee</p><p><bold>Drafting of the manuscript:</bold>&#x000a0; Christine Son, Nirmal Desai, Jeff Leya, Promila Banerjee</p><p><bold>Critical review of the manuscript for important intellectual content:</bold>&#x000a0; Christine Son, Nirmal Desai, Jeff Leya, Promila Banerjee, Joshua Kalapala</p><p><bold>Supervision:</bold>&#x000a0; Promila Banerjee</p></fn></fn-group><ref-list><title>References</title><ref id="REF1"><label>1</label><element-citation publication-type="journal"><article-title>History of Helicobacter pylori, duodenal ulcer, gastric ulcer and gastric cancer</article-title><source>World J Gastroenterol</source><person-group>
<name><surname>Graham</surname><given-names>DY</given-names></name>
</person-group><fpage>5191</fpage><lpage>5204</lpage><volume>20</volume><year>2014</year><pub-id pub-id-type="pmid">24833849</pub-id>
</element-citation></ref><ref id="REF2"><label>2</label><element-citation publication-type="journal"><article-title>Diagnosis and treatment of nonsteroidal anti-inflammatory drug-associated upper gastrointestinal toxicity</article-title><source>Gastroenterol Clin North Am</source><person-group>
<name><surname>Cappell</surname><given-names>MS</given-names></name>
<name><surname>Schein</surname><given-names>JR</given-names></name>
</person-group><fpage>97</fpage><lpage>0</lpage><page-range>97-124, vi</page-range><volume>29</volume><year>2000</year><pub-id pub-id-type="pmid">10752019</pub-id>
</element-citation></ref><ref id="REF3"><label>3</label><element-citation publication-type="journal"><article-title>The pathophysiology of non-steroidal anti-inflammatory drug (NSAID)-induced mucosal injuries in stomach and small intestine</article-title><source>J Clin Biochem Nutr</source><person-group>
<name><surname>Matsui</surname><given-names>H</given-names></name>
<name><surname>Shimokawa</surname><given-names>O</given-names></name>
<name><surname>Kaneko</surname><given-names>T</given-names></name>
<name><surname>Nagano</surname><given-names>Y</given-names></name>
<name><surname>Rai</surname><given-names>K</given-names></name>
<name><surname>Hyodo</surname><given-names>I</given-names></name>
</person-group><fpage>107</fpage><lpage>111</lpage><volume>48</volume><year>2011</year><pub-id pub-id-type="pmid">21373261</pub-id>
</element-citation></ref><ref id="REF4"><label>4</label><element-citation publication-type="journal"><article-title>Hormonal regulation of gastric acid in peptic ulcer disease</article-title><source>Scand J Gastroenterol Suppl</source><person-group>
<name><surname>Lamers</surname><given-names>CB</given-names></name>
</person-group><fpage>5</fpage><lpage>10</lpage><volume>146</volume><year>1988</year><pub-id pub-id-type="pmid">2906469</pub-id>
</element-citation></ref><ref id="REF5"><label>5</label><element-citation publication-type="journal"><article-title>Calcium carbonate antacid and serum gastrin concentration in duodenal ulcer</article-title><source>Surg Forum</source><person-group>
<name><surname>Reeder</surname><given-names>DD</given-names></name>
<name><surname>Conlee</surname><given-names>JL</given-names></name>
<name><surname>Thompson</surname><given-names>JC</given-names></name>
</person-group><fpage>308</fpage><lpage>310</lpage><volume>22</volume><year>1971</year><uri xlink:href="https://pubmed.ncbi.nlm.nih.gov/5121384/">https://pubmed.ncbi.nlm.nih.gov/5121384/</uri><pub-id pub-id-type="pmid">5121384</pub-id>
</element-citation></ref><ref id="REF6"><label>6</label><element-citation publication-type="journal"><article-title>Stimulation of gastric secretion and gastrin release by single oral doses of calcium carbonate in man</article-title><source>N Engl J Med</source><person-group>
<name><surname>Levant</surname><given-names>JA</given-names></name>
<name><surname>Walsh</surname><given-names>JH</given-names></name>
<name><surname>Isenberg</surname><given-names>JI</given-names></name>
</person-group><fpage>555</fpage><lpage>558</lpage><volume>289</volume><year>1973</year><pub-id pub-id-type="pmid">4723104</pub-id>
</element-citation></ref><ref id="REF7"><label>7</label><element-citation publication-type="journal"><article-title>Effects of induced hypercalcemia on human gastric secretion</article-title><source>Gastroenterology</source><person-group>
<name><surname>Barreras</surname><given-names>RF</given-names></name>
<name><surname>Donaldson RM</surname><given-names>Jr</given-names></name>
</person-group><fpage>670</fpage><lpage>675</lpage><volume>52</volume><year>1967</year><uri xlink:href="https://pubmed.ncbi.nlm.nih.gov/5336657/">https://pubmed.ncbi.nlm.nih.gov/5336657/</uri><pub-id pub-id-type="pmid">5336657</pub-id>
</element-citation></ref><ref id="REF8"><label>8</label><element-citation publication-type="journal"><article-title>Acid secretion after calcium carbonate in patients with duodenal ulcer</article-title><source>N Engl J Med</source><person-group>
<name><surname>Barreras</surname><given-names>RF</given-names></name>
</person-group><fpage>1402</fpage><lpage>1405</lpage><volume>282</volume><year>1970</year><pub-id pub-id-type="pmid">4910837</pub-id>
</element-citation></ref><ref id="REF9"><label>9</label><element-citation publication-type="journal"><article-title>Calcium stimulation of gastrin and gastric acid secretion: effect of small doses of calcium carbonate</article-title><source>Gut</source><person-group>
<name><surname>Behar</surname><given-names>J</given-names></name>
<name><surname>Hitchings</surname><given-names>M</given-names></name>
<name><surname>Smyth</surname><given-names>RD</given-names></name>
</person-group><fpage>442</fpage><lpage>448</lpage><volume>18</volume><year>1977</year><pub-id pub-id-type="pmid">873325</pub-id>
</element-citation></ref><ref id="REF10"><label>10</label><element-citation publication-type="journal"><article-title>I calciomimetici (Article in Italian)</article-title><source>G Ital Nefrol</source><person-group>
<name><surname>Messa</surname><given-names>P</given-names></name>
<name><surname>Como</surname><given-names>G</given-names></name>
<name><surname>Brezzi</surname><given-names>B</given-names></name>
</person-group><fpage>12</fpage><lpage>21</lpage><volume>23</volume><year>2006</year><uri xlink:href="http://www.nephromeet.com/web/eventi/GIN/dl/storico/2006/gin_1_2006/12-Messa-21.pdf">http://www.nephromeet.com/web/eventi/GIN/dl/storico/2006/gin_1_2006/12-Messa-21.pdf</uri><pub-id pub-id-type="pmid">16521071</pub-id>
</element-citation></ref><ref id="REF11"><label>11</label><element-citation publication-type="journal"><article-title>Activation of the calcium sensing receptor stimulates gastrin and gastric acid secretion in healthy participants</article-title><source>Osteoporos Int</source><person-group>
<name><surname>Ceglia</surname><given-names>L</given-names></name>
<name><surname>Harris</surname><given-names>SS</given-names></name>
<name><surname>Rasmussen</surname><given-names>HM</given-names></name>
<name><surname>Dawson-Hughes</surname><given-names>B</given-names></name>
</person-group><fpage>71</fpage><lpage>78</lpage><volume>20</volume><year>2009</year><pub-id pub-id-type="pmid">18536954</pub-id>
</element-citation></ref><ref id="REF12"><label>12</label><element-citation publication-type="journal"><article-title>The efficacy and safety of cinacalcet in primary hyperparathyroidism: a systematic review and meta-analysis of randomized controlled trials and cohort studies</article-title><source>Rev Endocr Metab Disord</source><person-group>
<name><surname>Chandran</surname><given-names>M</given-names></name>
<name><surname>Bilezikian</surname><given-names>JP</given-names></name>
<name><surname>Lau</surname><given-names>J</given-names></name>
<name><surname>Rajeev</surname><given-names>R</given-names></name>
<name><surname>Yang</surname><given-names>SP</given-names></name>
<name><surname>Samuel</surname><given-names>M</given-names></name>
<name><surname>Parameswaran</surname><given-names>R</given-names></name>
</person-group><fpage>485</fpage><lpage>501</lpage><volume>23</volume><year>2022</year><pub-id pub-id-type="pmid">35041148</pub-id>
</element-citation></ref><ref id="REF13"><label>13</label><element-citation publication-type="journal"><article-title>The efficacy and safety of medical and surgical therapy in patients with primary hyperparathyroidism: a systematic review and meta-analysis of randomized controlled trials</article-title><source>J Bone Miner Res</source><person-group>
<name><surname>Ye</surname><given-names>Z</given-names></name>
<name><surname>Silverberg</surname><given-names>SJ</given-names></name>
<name><surname>Sreekanta</surname><given-names>A</given-names></name>
<etal/>
</person-group><fpage>2351</fpage><lpage>2372</lpage><volume>37</volume><year>2022</year><pub-id pub-id-type="pmid">36053960</pub-id>
</element-citation></ref><ref id="REF14"><label>14</label><element-citation publication-type="journal"><article-title>Primary hyperparathyroidism</article-title><source>Curr Probl Surg</source><person-group>
<name><surname>Wells SA</surname><given-names>Jr</given-names></name>
<name><surname>Leight</surname><given-names>GS</given-names></name>
<name><surname>Ross AJ</surname><given-names>3rd</given-names></name>
</person-group><fpage>398</fpage><lpage>463</lpage><volume>17</volume><year>1980</year><uri xlink:href="http://pubmed.ncbi.nlm.nih.gov/6998661/">http://pubmed.ncbi.nlm.nih.gov/6998661/</uri><pub-id pub-id-type="pmid">6998661</pub-id>
</element-citation></ref><ref id="REF15"><label>15</label><element-citation publication-type="journal"><article-title>Perforated gastric ulcer as the initial manifestation of hyperparathyroidism</article-title><source>BMJ Case Rep</source><person-group>
<name><surname>Castle</surname><given-names>C</given-names></name>
<name><surname>Tietjens</surname><given-names>J</given-names></name>
</person-group><fpage>0</fpage><volume>14</volume><year>2021</year></element-citation></ref><ref id="REF16"><label>16</label><element-citation publication-type="journal"><article-title>Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis</article-title><source>N Engl J Med</source><person-group>
<name><surname>Block</surname><given-names>GA</given-names></name>
<name><surname>Martin</surname><given-names>KJ</given-names></name>
<name><surname>de Francisco</surname><given-names>AL</given-names></name>
<etal/>
</person-group><fpage>1516</fpage><lpage>1525</lpage><volume>350</volume><year>2004</year><pub-id pub-id-type="pmid">15071126</pub-id>
</element-citation></ref><ref id="REF17"><label>17</label><element-citation publication-type="journal"><article-title>Cinacalcet: An oral calcimimetic agent for the management of hyperparathyroidism</article-title><source>Clin Ther</source><person-group>
<name><surname>Dong</surname><given-names>BJ</given-names></name>
</person-group><fpage>1725</fpage><lpage>1751</lpage><volume>27</volume><year>2005</year><pub-id pub-id-type="pmid">16368445</pub-id>
</element-citation></ref><ref id="REF18"><label>18</label><element-citation publication-type="journal"><article-title>Cinacalcet effect on severe hyperparathyroidism</article-title><source>Saudi J Kidney Dis Transpl</source><person-group>
<name><surname>Al Saran</surname><given-names>K</given-names></name>
<name><surname>Sabry</surname><given-names>A</given-names></name>
<name><surname>Yehia</surname><given-names>A</given-names></name>
<name><surname>Molhem</surname><given-names>A</given-names></name>
</person-group><fpage>867</fpage><lpage>871</lpage><volume>21</volume><year>2010</year><uri xlink:href="http://20814122">http://20814122</uri><pub-id pub-id-type="pmid">20814122</pub-id>
</element-citation></ref></ref-list></back></article>